- Home
- SEVN vs ASMB Comparison
SEVN vs ASMB Comparison
Compare SEVN & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- ASMB
- Stock Information
- Founded
- SEVN 1986
- ASMB 2005
- Country
- SEVN United States
- ASMB United States
- Employees
- SEVN N/A
- ASMB N/A
- Industry
- SEVN Real Estate Investment Trusts
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- ASMB Health Care
- Exchange
- SEVN Nasdaq
- ASMB Nasdaq
- Market Cap
- SEVN 156.9M
- ASMB 141.8M
- IPO Year
- SEVN N/A
- ASMB 2010
- Fundamental
- Price
- SEVN $10.50
- ASMB $25.44
- Analyst Decision
- SEVN Strong Buy
- ASMB Strong Buy
- Analyst Count
- SEVN 2
- ASMB 3
- Target Price
- SEVN $13.50
- ASMB $33.00
- AVG Volume (30 Days)
- SEVN 78.3K
- ASMB 90.8K
- Earning Date
- SEVN 07-28-2025
- ASMB 08-06-2025
- Dividend Yield
- SEVN 10.67%
- ASMB N/A
- EPS Growth
- SEVN N/A
- ASMB N/A
- EPS
- SEVN 1.04
- ASMB N/A
- Revenue
- SEVN $29,272,000.00
- ASMB $33,247,000.00
- Revenue This Year
- SEVN $7.45
- ASMB $0.04
- Revenue Next Year
- SEVN $1.12
- ASMB N/A
- P/E Ratio
- SEVN $10.08
- ASMB N/A
- Revenue Growth
- SEVN N/A
- ASMB 54.77
- 52 Week Low
- SEVN $10.01
- ASMB $7.75
- 52 Week High
- SEVN $14.66
- ASMB $25.62
- Technical
- Relative Strength Index (RSI)
- SEVN 42.65
- ASMB 78.89
- Support Level
- SEVN $10.20
- ASMB $16.90
- Resistance Level
- SEVN $10.95
- ASMB $24.71
- Average True Range (ATR)
- SEVN 0.24
- ASMB 1.56
- MACD
- SEVN 0.08
- ASMB 0.59
- Stochastic Oscillator
- SEVN 52.13
- ASMB 97.94
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.